Acurx Pharmaceuticals (NASDAQ:ACXP) Releases Earnings Results, Beats Expectations By $0.03 EPS

Acurx Pharmaceuticals (NASDAQ:ACXP) released its quarterly earnings data on Monday. The company reported ($0.11) earnings per share for the quarter, beating the consensus estimate of ($0.14) by $0.03, Zacks reports.

Acurx Pharmaceuticals Price Performance

NASDAQ:ACXP traded down $0.01 on Tuesday, hitting $0.39. 151,085 shares of the company’s stock were exchanged, compared to its average volume of 160,695. The firm has a 50-day moving average price of $0.40 and a 200-day moving average price of $0.81. Acurx Pharmaceuticals has a 52 week low of $0.30 and a 52 week high of $3.33. The company has a market cap of $8.69 million, a P/E ratio of -0.36 and a beta of -1.37.

Wall Street Analysts Forecast Growth

Separately, HC Wainwright restated a “buy” rating and set a $12.00 target price on shares of Acurx Pharmaceuticals in a report on Wednesday, March 19th.

About Acurx Pharmaceuticals

Acurx Pharmaceuticals, Inc, a clinical stage biopharmaceutical company, develops antibiotics to treat bacterial infections. The company's lead antibiotic candidate is ibezapolstat, a novel mechanism of action that targets the polymerase IIIC enzyme that is in Phase 2b clinical trial to treat patients with clostridium difficile infections.